Alpha CTX as a biomarker of skeletal invasion of breast cancer: Immunolocalization and the load dependency of urinary excretion

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 7, 2006, Pages 1392-1395

  Leeming, Diana J ^a   Delling, Günter ^b   Koizumi, Mitsuru ^c   Henriksen, Kim ^a   Karsdal, Morten A ^a   Li, Bo ^a   Qvist, Per ^a   Tankó, László B ^d   Byrjalsen, Inger ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CYTOKERATIN; CYTOKERATIN ANTIBODY;

ADULT; ARTICLE; BODY MASS; BONE METASTASIS; BONE TISSUE; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MAJOR CLINICAL STUDY; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; TUMOR CELL; URINARY EXCRETION;

BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN TYPE I; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; OSTEOCLASTS; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 33746395438     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0909     Document Type: Article

References (12)

1. Cloos PAC, Lyubimova N, Solberg H, et al. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 2004;50:279-89.
2. Houzé P, Bellik B, Extra JM, Bouro F, Bousquet B. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer. Clin Chim Acta 1999;281:77-88.
3. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tankó LB. The relative utility of eight collagenous and non-collagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:32-8.
4. Cloos PAC, Fledelius C, Christgau S, et al. Investigation of bone disease using isomerized and racemized fragments of type I collagen. Calcif Tissue Int 2003;72:8-17.
5. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;16:195-202.
6. Leeming DJ, Koizumi M, Li B, et al. Non-isomerized C-telopeptides of type I collagen (αCTX): a sensitive indicator of metastatic bone disease. J Bone Miner Res 2005;20:S65.
7. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54.
8. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005;35:135-42.
9. Brown B, Laorr A, Greenspan A, Stadalnik R. Negative bone scintigraphy with diffuse osteoblastic breast carcinoma metastases. Clin Nucl Med 1993;19:194-6.
10. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005;12:549-83.
11. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-8.
12. Wittrant Y, Théoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57.